Brief: Enlivex And Mount Sinai Health System Announce Research Collaboration For The Development Of Allocetra In Combination With Immune Checkpoint Inhibitors
01/03/2021 13:58
March 1 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX AND MOUNT SINAI HEALTH SYSTEM ANNOUNCE RESEARCH
COLLABORATION FOR THE DEVELOPMENT OF ALLOCETRA IN COMBINATION
WITH IMMUNE CHECKPOINT INHIBITORS
Source text for Eikon: ID:nGNX89QntD
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment